drugset / Trial / NCT00199251

Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria

NCT00199251

Phase 3 Terminated 300 enrolled J. Uriach and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

· To evaluate the efficacy of rupatadine 10 and 20 mg for the treatment of CIU symptoms over four-week treatment period in comparison with placebo.

Timeline

Start
2004-04
Primary completion
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Rupatadine Small molecule 10 mg
Subject Rupatadine Small molecule 20 mg

Indications